Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers

References

• Nanishi E, Levy O, Ozonoff A. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Hum Vaccin Immunother. 2022;18(5):2045857. doi:10.1080/21645515.2022.2045857.
   PubMed Web of Science ®Google Scholar
• Kodera S, Rashed EA, Hirata A. Estimation of real-world vaccination effectiveness of mRNA COVID-19 vaccines against delta and omicron variants in Japan. Vaccines (Basel). 2022;10(3):430. PMID: 35335062; PMCID: PMC8953128. doi:10.3390/vaccines10030430.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray S, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–6. doi:10.1016/S0140-6736(21)02183-8.
   PubMed Web of Science ®Google Scholar
• Can G, Acar HC, Aydin SN, Balkan II, Karaali R, Budak B, Saltoglu N. Waning effectiveness of CoronaVac in real life: a retrospective cohort study in health care workers. Vaccine. 2022;40(18):2574–9. doi:10.1016/j.vaccine.2022.03.032.
   PubMed Web of Science ®Google Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21. doi:10.1016/j.cmi.2021.10.005.
   PubMed Web of Science ®Google Scholar
• WHO. Interim statement on COVID-19 vaccine booster doses. [accessed 2022 Apr 20]. https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccinebooster-doses.
   Google Scholar
• Juno JA, Wheatley AK. Boosting immunity to COVID-19 vaccines. Nat Med. 2021;27(11):1874–5. doi:10.1038/s41591-021-01560-x.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, Ramsay M, Lopez Bernal J. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. 2022;28(4):831–7. doi:10.1038/s41591-022-01699-1.
   PubMed Web of Science ®Google Scholar
• Turkish medicines and medical devices agency. [accessed 2022 Apr 20]. https://www.titck.gov.tr/haber/kamuoyunun-dikkatine-13012021185623.
   Google Scholar
• Turkey Ministry of Health. List of COVID-19 vaccination groups. [accessed 2022 Apr 20]. https://covid19asi.saglik.gov.tr/EN-80295/list-of-covid-19-vaccination-groups.html.
   Google Scholar
• Turkey Ministry of Health. [accessed 2022 Apr 20]. https://www.saglik.gov.tr/EN,81812/minister-koca-receives-questions-from-parliamentary-reporters.html.
   Google Scholar
• Turkey Ministry of Health. [accessed 2022 Apr 20]. https://www.saglik.gov.tr/TR,84343/koronavirus-bilim-kurulu-toplantisina-iliskin-aciklama-30062021.html.
   Google Scholar
• Reuters. [accessed 2022 Apr 20]. https://www.reuters.com/world/middle-east/turkey-offering-extra-pfizer-shots-those-wanting-travel-2021-08-16/.
   Google Scholar
• DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, Alter G, Amara RR, Baric RS, Barouch DH, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022;605(7911):640–52. doi:10.1038/s41586-022-04690-5.
   PubMed Web of Science ®Google Scholar
• Vitiello A, Ferrara F, Troiano V, La Porta R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology. 2021;29(5):1357–60. doi:10.1007/s10787-021-00847-2.
   PubMed Web of Science ®Google Scholar
• Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, Ben-Ami R. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021;325(24):2457–65. doi:10.1001/jama.2021.7152.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22. doi:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, Lee VJ, Tan KB. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 infection and severe disease in Singapore. Clin Infect Dis. 2022;75(8):1442–5. doi:10.1093/cid/ciac288.
   PubMed Web of Science ®Google Scholar
• Katz MA, Rojas Castro MY, Seyidov N, Herdman MT, Mehdiyev S, McKnight CJ, Guseinova A, Cojocaru R, Doran J, Mühlemann B, et al. The effectiveness of primary series CoronaVac vaccine in preventing COVID-19 illness: a prospective cohort study among healthcare workers in Azerbaijan, May–November 2021. Influenza Other Respir Viruses. 2023;17(10):e13147. doi:10.1111/irv.13147.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Zubizarreta JR, González C, Pizarro A, Acevedo J, Leo K, Paredes F, Bralic T, Vergara V, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–e806. doi:10.1016/S2214-109X(22)00112-7.
   PubMed Web of Science ®Google Scholar
• Suah JL, Tng BH, Tok PSK, Husin M, Thevananthan T, Peariasamy KM, Sivasampu S. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against delta and omicron SARS-CoV-2 infection. Emerg Microbes Infect. 2022;11(1):1343–5. doi:10.1080/22221751.2022.2072773.
   PubMed Web of Science ®Google Scholar
• Barin B, Kasap U, Selçuk F, Volkan E, Uluçkan Ö. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe. 2022;3(4):e274–e83. doi:10.1016/S2666-5247(21)00305-0.
   PubMedGoogle Scholar
• Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–9. doi:10.1016/S0140-6736(22)00094-0.
   PubMed Web of Science ®Google Scholar
• Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, Beltrán C, Castillo-Delgado L, Contreras-Benavides X, Acevedo ML, et al. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Med. 2022;20(1):216. doi:10.1186/s12916-022-02406-0.
   PubMed Web of Science ®Google Scholar
• Yavuz E, Günal Ö, Başbulut E, Şen A. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. J Med Virol. 2022;94(8):3768–75. doi:10.1002/jmv.27794.
   PubMed Web of Science ®Google Scholar
• Fadlyana E, Setiabudi D, Kartasasmita CB, Putri ND, Rezeki Hadinegoro S, Mulholland K. BCOV21 study group. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdox1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia. Lancet Infect Dis. 2023;23(5):S1473-3099(22)00800–3. doi:10.1016/S1473-3099(22)00800-3.
   Web of Science ®Google Scholar
• Saltoğlu N, Dinç HÖ, Balkan İİ, Can G, Özbey D, Beytur AN, Keskin E, Budak B, Aydoğan O, Mete B, et al. Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs. Diagn Microbiol Infect Dis. 2022;104(2):115758. doi:10.1016/j.diagmicrobio.2022.115758.
   PubMed Web of Science ®Google Scholar
• Çağlayan D, Süner AF, Şiyve N, Güzel I, Irmak Ç, Işik E, Appak Ö, Çelik M, Öztürk G, Alp Çavuş S, et al. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. J Med Virol. 2022;94(5):2212–21. doi:10.1002/jmv.27620.
   PubMed Web of Science ®Google Scholar
• Gareayaghi N, Demirci M, Ozbey D, Dasdemir F, Dinc HO, Balkan II, Saribas S, Saltoglu N, Kocazeybek B. Comparison of SARS-CoV-2 antibody levels after a third heterologous and homologous BNT162b2 booster dose. Vaccines (Basel). 2022;10(10):1672. doi:10.3390/vaccines10101672.
   PubMed Web of Science ®Google Scholar
• Uzun O, Akpolat T, Varol A, Turan S, Bektas SG, Cetinkaya PD, Dursun M, Bakan N, Ketencioglu BB, Bayrak M, et al. COVID-19: vaccination vs. hospitalization. Infection. 2022;50(3):747–52. doi:10.1007/s15010-021-01751-1.
   PubMed Web of Science ®Google Scholar
• Aykurt O. İki Doz Coronavac Aşısı Sonrası Heterolog veya Homolog Rapel Dozun Etkinliği, Çankırı Örneği. Avrasya Sağlık Bilimleri Dergisi. 2022;6(1):16–20. doi:10.53493/avrasyasbd.1157196.
   Google Scholar
• Sonmezer MC, Dizman GT, Erul E, Sahin TK, Saricaoglu T, Alp A, Tanriover MD, Uzun O, Unal S, Akova M, et al. Relative vaccine effectiveness of the third dose of CoronaVac or BNT162b2 following a two-dose CoronaVac regimen: a prospective observational cohort study from an adult vaccine center in Turkey. Vaccines (Basel). 2022;10(7):1140. doi:10.3390/vaccines10071140.
   PubMed Web of Science ®Google Scholar
• Parums DV. Editorial: a rapid global increase in COVID-19 is due to the emergence of the EG.5 (Eris) subvariant of omicron SARS-CoV-2. Med Sci Monit. 2023;29:e942244. doi:10.12659/MSM.942244.
   PubMed Web of Science ®Google Scholar